SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics, Inc., a clinical-stage oncology company developing safer and more effective cancer treatments through its nanotechnology platform, announced a collaboration with the University of Chicago, in Chicago, Illinois. The research will be conducted at the University of Chicago Ludwig Center for Metastasis Research by investigators Stephen J. Kron MD-PhD and Ralph R. Weichselbaum MD. The researchers hope to develop a new application for the investigational drug ATI-1123, a proprietary formulation of the chemotherapy agent docetaxel, commonly known as Taxotere, manufactured using Azaya’s patented Protein Stabilized Liposomes™ (PSL) process. The goal is to determine whether a low, clinically safe dose of radiation can significantly enhance delivery of ATI-1123 to experimental tumors in laboratory mice. The study will also document the effects of radiation on docetaxel accumulation in the irradiated tumors, and examine whether the combination leads to greater inhibition of tumor growth. This work may serve as a model for future clinical studies in cancer patients undergoing radiation therapy.
Help employers find you! Check out all the jobs and post your resume.
